TD Cowen lowered the firm’s price target on Johnson & Johnson to $185 from $195 and keeps a Buy rating on the shares. The firm said Q2 performance was solid as the company maintained its 2024 adjusted operational sales growth guidance but said the negative impact from recent M&A was offset by an improved performance outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Stock Market News Today, 7/17/24 – Nasdaq Sinks Almost 3%; Housing Data Beats Estimates
- JNJ Earnings: Johnson & Johnson’s Q2 Results Top Estimates
- Options Volatility and Implied Earnings Moves Today, July 17, 2024
- Johnson & Johnson cuts FY24 adjusted EPS to $10.00-$10.10 from $10.60-$10.75
- Johnson & Johnson reports Q2 adjusted EPS $2.82, consensus $2.70